Tarsus CMO sells 11,578 shares in plan trades
Tarsus Pharmaceuticals’ chief medical officer disclosed pre-planned open-market stock sales totaling 11,578 shares over two days in early September 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold a total of 11,578 shares of common stock on September 1–2, 2026, at prices between $73.86 and $80.00 per share, including indirect sales through a spouse’s Roth IRA, under Rule 10b5-1 trading plans.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 5,387 | $80.00 | $431K |
| Sale | Common Stock F2 | 1,590 | $80.00 | $127K |
| Sale | Common Stock F1 | 4,601 | $73.86 | $340K |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
- F2. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Roth IRA financial
401(k) Plan financial
indirect ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did TARS disclose for Chief Medical Officer Elizabeth Yeu Lin?
Were the September 2026 TARS insider sales made under a Rule 10b5-1 plan?
What indirect TARS holdings does the Form 4 show after the transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.